Here, we took advantage of the observation that RU486 is therapeutic for two extremely common tumors of women—breast cancer and uterine leiomyoma—and used massive parallel sequencing of immunoprecipitated DNA fragments to identify PR-interaction sites in response to RU486. The gene discussed is PGR; the disease is breast cancer.